6365741878112

Laahn Foster, MD, Division of Hematology-Oncology, University of Virginia, discusses an analysis of the phase 3 AURIGA study (NCT03901963), evaluating daratumumab (Darzalex) plus lenalidomide (Revlimid) vs lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma after transplant. These results were presented at the 

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


ASH Annual Meeting and Exposition

Laahn Foster, MD, shares data on daratumumab and lenalidomide vs lenalidomide alone as maintenance in newly diagnosed multiple myeloma after transplant.

Dr Foster on Daratumumab Plus Lenalidomide in Newly Diagnosed Myeloma After Transplant